Amicus Therapeutics In New Jersey For Rare Diseases

Amicus Therapeutics in New Jersey for rare diseases is a world bioengineering business organization that is scientifically driven with treatment for a few annihilative diseases that are uncommon and orphan. A rare disease is orphan when there is not enough support and resources for it on the market, but at least there are government grants available to help.

 

Amicus Therapeutics’s passion drives their dedication to’ new medical care for rare disease victims. They claim, ” Dedication to patients and their families is what drives us to truly provide healing beyond disease.”

 

Furthermore, there is only a single person currently diagnosed with the rarest disease around the entire globe. It is that of Ribose-5-phosphate isomerase deficiency or RPI deficiency. In fact, there are over 7000 rare diseases known right now.

 

Indeed, Amicus Therapeutics has a Fabry disease program. They are also developing an oral drug called migalastat for the treatment of this rare disease. Fabry disease is an X-linked malady caused by chromosomal variation in the GLA factor.

 

What is more, blistering and skin lesions are characteristics of Epidermolysis Bullosa, or EB (https://finance.yahoo.com/quote/FOLD?ltr=1)? This rare, inherited disorder sometimes has the physical manifestations of those two matters, and possibly the lining of other body organs. EB is disfiguring, one can get an infection with brutal wounds, and in some cases it is fatal.

 

Likewise, Pompe disease comes via heredity as Lysosomal Storage Disorder (LSD). It is caused by not having enough of the enzyme acid alpha-glucosidase (GAA). When there is not enough in the body, it leads to an accumulation of the glycogen in muscles and tissues. At this time, there are not any treatments approved for the disease yet.

Also, Amicus Therapeutics has a pipeline program for

 

In any case, Amicus Therapeutics benefits are advanced product pipeline and plan technologies which certainly put Amicus Therapeutics at the forefront of developments that will take care of the unmet needs of people with rare diseases (Indeed).

 

Leave a Reply

Your email address will not be published. Required fields are marked *